Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________________ FORM 10-Q ___________________________________________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________to_ ...

AtriCure (ATRC) Q1 2025 Earnings Call April 29, 2025 09:28 PM ET Speaker0 Good afternoon and welcome to AtriCure's First Quarter twenty twenty five Earnings Conference Call. This call is being recorded for replay purposes. And at this time, all participants are in listen only mode. We will be facilitating a question and answer session following prepared remarks from AtriCure's management. I would now like to turn the call over to Marissa Beisch from the Gilmartin Group for a few introductory comments. Speak ...

Shares of AtriCure have returned +4.4% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. United States Revenue- Pain management: $17.27 million compared to the $16.17 million average estimate based on three analysts. The reported number represents a change of +35.6% year over year. International Revenue- Pain management: $1.79 million versus $1.92 million es ...

Revenue for the first quarter 2025 was $123.6 million, an increase of 13.6% over first quarter 2024 revenue (14.1% on a constant currency basis), reflecting continued global adoption of our products and therapies for the treatment of Afib, LAA management and post-operative pain management. U.S. revenue was $101.1 million, an increase of $10.9 million or 12.1%, compared to the first quarter 2024. U.S. revenue growth was driven by sales across key product lines, including the EnCompass clamp in open ablation, ...

Atrial Fibrillation (Afib) Overview - Atrial fibrillation (Afib) affects over 59 million people globally, with over 4 million in the U.S. suffering from long-standing persistent Afib[18]. - Afib is responsible for approximately 15% to 20% of the estimated 800,000 strokes annually in the U.S., highlighting the condition's significant healthcare cost burden[24]. - The increasing awareness and improved diagnostic screening for Afib are expected to lead to a higher number of diagnosed patients over time[21]. Market Opportunities - The market for cardiac ablation products represents a significant growth opportunity, with an estimated 300,000 potential candidates for surgical ablation annually, of which less than 20% are currently treated[23]. - Approximately 500,000 Afib patients are treated by catheter ablation each year in the U.S., with an expected growth rate of over 10% annually[25]. - The market for pain management ablation products is significant, with approximately 150,000 thoracic procedures and 250,000 cardiothoracic procedures performed annually in the U.S.[25]. - The company’s AtriClip system is believed to be safer and more effective for left atrial appendage (LAA) management, addressing a significant market opportunity due to the high incidence of strokes related to Afib[24]. - The company’s products are sold through direct sales and distributors in various international markets, primarily transacted in U.S. Dollars[20]. Product Development and Innovation - The EPi-Sense System, approved in 2021, is the only FDA-approved minimally invasive procedure for treating long-standing persistent Afib, demonstrating the company's commitment to innovative solutions[33]. - The AtriClip LAA Exclusion System is designed to exclude the left atrial appendage, providing electrical isolation benefits and reducing the risk of blood clots[35]. - The AtriClip FLEX-Mini device, launched in 2024, sets a new standard as the smallest profile for a surgical LAA device on the market[37]. - In 2022, the company launched the EnCompass clamp in the U.S., designed to improve efficiency in cardiac soft tissue ablation, and received 510(k) clearance for the EnCapture clamp in 2024[29]. - The cryoSPHERE MAX probe, launched in 2024, reduces freeze times by 50% compared to the first generation cryoSPHERE probe, enhancing pain management capabilities[34]. Clinical Trials and Research - The company continues to invest in clinical trials to validate long-term results of its products, including the ICE-AFIB trial for the cryoICE system[32][40]. - The HEAL-IST clinical trial aims to enroll up to 142 patients across 40 sites in the US, UK, and EU, focusing on the safety and efficacy of a hybrid ablation procedure for Inappropriate Sinus Tachycardia[48]. - The CONVERGE trial demonstrated a 29% absolute difference in efficacy at 12 months (78% relative improvement) for the hybrid therapy arm compared to endocardial catheter ablation alone in long-standing persistent Afib patients[49]. - The ICE-AFIB study completed twelve-month patient follow-up, analyzing the safety and efficacy of the cryoICE system for persistent Afib treatment[57]. - The CEASE-AF trial demonstrated superior freedom from atrial arrhythmias for staged hybrid ablation compared to endocardial catheter ablation, with results accepted for presentation at the 2025 EHRA meeting[57]. Financial Performance and Risks - The company reported net losses of $44,698 in 2024, $30,438 in 2023, and $46,466 in 2022, with an accumulated deficit of $401,755 as of December 31, 2024[167]. - The company faces significant financial risks due to fluctuating quarterly results, which may be impacted by the pace of product adoption and external economic conditions[166]. - A prolonged economic downturn could adversely impact procedure volumes and hospital staffing, leading to reduced revenue[118]. - The company may need to raise capital in the future, which could dilute stockholder ownership and cause a decline in stock price[180]. - The company has a compliance program in place to mitigate risks associated with anti-corruption laws, but potential violations could lead to severe penalties and impact financial statements[163]. Regulatory and Compliance Challenges - The company is an FDA-registered medical device manufacturer and certified to ISO 13485:2016, conducting regular audits of its quality systems and suppliers[87]. - Regulatory challenges, including compliance with FDA requirements, could hinder product approval and market adoption[116]. - The company has not received FDA clearance to promote certain products for the treatment of Afib, which could hinder its ability to grow and maintain its business[145]. - The company is subject to medical device reporting regulations, and failure to report adverse events could result in significant regulatory fines or penalties[144]. - A serious failure to comply with regulatory requirements could result in sanctions such as warning letters, fines, and even criminal prosecution, adversely affecting the company's operations and financial condition[143]. Employee and Organizational Culture - The company has approximately 1,300 employees as of December 31, 2024, with a voluntary turnover rate consistently below 12% over the last five years, outperforming the industry average for medical device companies[89]. - The company has been recognized as a Top Workplace nine times in the past ten years and has been voted a Great Place to Work for three consecutive years[91]. - The company has invested in various employee development programs, including leadership development and competency-based courses, to enhance talent management and retention[93]. - The company has implemented a DE&I framework aimed at attracting diverse talent and fostering an inclusive workplace, earning recognition for providing opportunities for women innovators in 2024[94][95]. - The company maintains a strong safety culture with multiple safety programs and evaluations, ensuring a safe workplace for all employees[99].

Investors might want to bet on AtriCure (ATRC) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual i ...

AtriCure, Inc. (NASDAQ:ATRC) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Rick Wise - Stifel Mike Matson - Needham & Company Danny Stauder - Citizens JMP Danielle Antalffy - UBS Suraj Kalia - Oppenheimer Matthe ...

AtriCure (ATRC) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 46.67%. A quarter ago, it was expected that this medical device maker would post a loss of $0.20 per share when it actually produced a loss of $0.17, delivering a surprise of 15%.Over the last four quarters, the company has surpa ...

Financial Results - AtriCure announced preliminary financial results for Q4 and full year 2024 on January 13, 2025[4] Investor Relations - The company is holding investor meetings to discuss business and growth strategy during the week of January 13, 2025[6] Forward-Looking Statements - The press release and investor presentation contain forward-looking statements regarding future performance and are subject to risks and uncertainties[7]

Analysts on Wall Street project that AtriCure (ATRC) will announce quarterly loss of $0.15 per share in its forthcoming report, representing an increase of 28.6% year over year. Revenues are projected to reach $124.3 million, increasing 16.7% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 1.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Pri ...